
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive February 2018 issue in an interactive PDF format.
almost 9 years ago
Pharma's Image Fix: Lessons from the Fieldalmost 9 years ago
The Innovation Distinction: Biopharma's Reputational Passalmost 9 years ago
Valeant’s Northern Facealmost 9 years ago
More New Drugs and Generics Reshape Pharma Marketsalmost 9 years ago
Leadership in All the Right Placesalmost 9 years ago
Industry Engine Check




